GH Research PLC logo

GH Research PLC

GHRS
Healthcare|Biotechnology|Ireland
$26.67
-0.74 (-2.72%)
Tangible Book
$4.24
Earnings Power
$4.29

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 0.92, 53.69, 283.87 ], "ebit_estimate": [ -96.66, -147.46, -174.55, -179.13, -50.52 ], "ebitda_estimate": [ -82.95, -120, -134.3, -195.8, -84.25 ], "net_income_estimate": [ -91.77, -138.41, -170.61, -176.55, -47.3 ], "per_share_eps_estimate": [ -1.4, -2, -2.25, -2.13, -0.74 ], "eps_nri_estimate": [ -1.4, -2, -2.25, -2.13, -0.98 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 4.85, 4.66, 5.45, 5.66, 5.19 ], "pretax_income_estimate": [ -93.84, -144.04, -170.61, -174.88, -47.3 ], "operating_cash_flow_per_share_estimate": [ -0.88, -1.52, -1.3, -2.31, -1.38 ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -26, -35.6, -31.4, -44.7, -11.2 ], "gross_margin_estimate": [ null, null, null, 61.67, 61.67 ], "operating_cash_flow_estimate": [ -54.59, -94.29, -80.64, -143.3, -85.61 ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -41.86, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -41.86, "future_eps_nri_estimate_growth": -41.86, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -43.19, "future_ebitda_estimate_growth": -31.45, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -52.19, "future_pretax_income_estimate_growth": -52.46, "future_book_value_per_share_estimate_growth": 5.43, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -16.36, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -26.63 }
quarterly
{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -21.04, -24.65, -30.18, null, null, null, null ], "ebitda_estimate": [ -19.8, -20.8, -23.8, null, null, null, null ], "net_income_estimate": [ -20.25, -23.75, -29.49, null, null, null, null ], "per_share_eps_estimate": [ -0.32, -0.36, -0.42, -0.35, -0.39, -0.43, -0.47 ], "eps_nri_estimate": [ -0.32, -0.36, -0.42, -0.35, -0.39, -0.43, -0.47 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 5.41, 5, 4.68, null, null, null, null ], "pretax_income_estimate": [ -20.25, -23.75, -29.36, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ -0.18, -0.22, -0.29, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ -11.17, -13.65, -17.99, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -41.86, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -41.86, "future_eps_nri_estimate_growth": -41.86, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -43.19, "future_ebitda_estimate_growth": -31.45, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -52.19, "future_pretax_income_estimate_growth": -52.46, "future_book_value_per_share_estimate_growth": 5.43, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -16.36, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -26.63 }